Tadaaki Arimura

St.Mary's Hospital (Fukuoka - Japan), Hukuoka, Fukuoka, Japan

Are you Tadaaki Arimura?

Claim your profile

Publications (9)16.33 Total impact

  • [show abstract] [hide abstract]
    ABSTRACT: Fifty-four patients were randomly divided into irbesartan and olmesartan groups. Blood pressure (BP) was significantly decreased in all patients at 12 weeks. In particular, BP in patients who initially received irbesartan showed significant reductions. The equality of variance of BP in the irbesartan group was significantly smaller than that in the olmesartan group at 12 weeks. Blood concentrations of adiponectin were significantly increased in the irbesartan group at 12 weeks. Log [pentraxin-3] in the irbesartan group were significantly decreased. In conclusion, the ability of irbesartan to reduce BP is comparable to that of olmesartan with equivalent safety.
    Clinical and Experimental Hypertension 05/2012; 34(5):342-9. · 1.28 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Little is known about the efficacy and safety of intensive lowering of low-density lipoprotein cholesterol (LDL-C) with statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. Fifty patients with stable angina were randomly divided into an atorvastatin (10 mg/day) (A) group and an atorvastatin (10 mg/day)/ezetimibe (10 mg/day) (A+E) group after stent implantation. Follow-up coronary angiography was performed at 6-9 months after stenting. The A and A+E groups showed significant reductions in LDL-C. The levels of LDL-C in the A+E group were significantly lower than those in the A group at follow-up, whereas there were no differences in major adverse cardiac events, in-stent restenosis, or in-stent % diameter stenosis (DS) between the groups. Only the A+E group showed a significant decrease in the levels of highly sensitive C-reactive protein. In a sub-analysis, %DS in the non-target vessel significantly decreased in both groups. Moreover, Δ%DS (Δ=the value at baseline minus that at follow-up) in the A+E group was more closely associated with LDL-C levels at follow-up than that in the A group. There were no significant differences in adverse effects between the A and A+E groups. In conclusion, although statin/ezetimibe therapy was effective and safe for intensive lipid-lowering in patients with stable angina after successful coronary stent implantation, improvement in clinical outcomes with the combination therapy remains unclear.
    Journal of Cardiology 04/2012; 60(2):111-8. · 2.30 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Many patients still have high blood pressure (BP) after treatment with high-dose angiotensin II type 1 receptor blockers (ARBs) or Preminent® (medium-dose of losartan (50 mg/day)/hydrochlorothiazide (HCTZ) (12.5 mg/day)). Therefore, we analyzed whether Micombi®BP (high-dose telmisartan (80 mg/day)/HCTZ (12.5 mg/day)) could provide better results with regard to efficacy and safety for patients with uncontrolled hypertension. In total, 44 hypertensive patients (22 males, age 71±14 years) who showed uncontrolled BP despite the use of high-dose ARBs or Preminent® were enrolled in this study. We used a changeover design in which the patients were switched from high-dose ARBs or Preminent® to Micombi®BP. We analyzed BP, heart rate (HR), and biochemical parameters before and after treatment for 3 months. Systolic BP and diastolic BP significantly decreased (125±15/69±11 mmHg) and 85% of the patients achieved their target BP at 3 months after changeover. Patients who switched from ARBs and those who switched from Preminent® showed similar BP-lowering effects. In addition, the reductions in BP after 3 months in patients with or without chronic kidney disease and in those with or without metabolic syndrome (MetS) were also similar. There were no significant changes in HR during the study period. Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects. High-dose telmisartan/HCTZ therapy was associated with a significant reduction in BP and helped patients achieve their target BP.
    Journal of Renin-Angiotensin-Aldosterone System 03/2012; 13(3):394-400. · 2.29 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Pigment epithelium-derived factor (PEDF) and pentosidine have received growing attention as sensitive biomarkers of the progression of atherosclerosis. The present study was performed to evaluate the utility of these biomarkers for assessing the effects of angiotensin II type 1 receptor blockers (ARBs). Sixty-three patients with coronary artery disease (CAD) following successful stent implantation were divided into an ARB group (n = 50), who initially received valsartan or olmesartan immediately following stent implantation, and a non-ARB group (n = 13) according to their blood pressure (BP) at baseline. Measurement of BP and blood sampling was performed prior to (at baseline) and 6-8 months following stent implantation (at follow-up). There were no significant differences in the baseline characteristics between the groups. Although there were no differences in the percentage of diameter re-stenosis between the groups, the BP level in the ARB group at follow-up showed a significant reduction and reached the target BP. The levels of plasma PEDF were significantly increased at follow-up in the ARB group, but not in the non-ARB group, while there were no differences in the levels of pentosidine between the groups. Changes in BP (ΔBP = BP at follow-up minus BP at baseline) were not associated with ΔPEDF. In conclusion, PEDF may be a useful biomarker for assessing the effects of ARBs independent of a reduction in BP.
    Journal of Renin-Angiotensin-Aldosterone System 02/2011; 12(3):320-5. · 2.29 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Although plasma pigment epithelium-derived factor (PEDF) levels have been shown to be significantly correlated with the levels of creatinine (Cr) in type 2 diabetes, little is known about the association between PEDF levels and renal dysfunction in patients with coronary artery disease (CAD). We enrolled 134 consecutive patients with diagnosed CAD and measured plasma levels of PEDF, serum Cr, uric acid (UA) and high-sensitive C-reactive protein (hsCRP). Plasma PEDF levels were positively correlated with serum Cr (p 〈 0.0001) and UA (p 〈 0.0001) and negatively correlated with the estimated glomerular filtration rate (eGFR) (p 〈 0.0001), whereas there was no association between plasma PEDF and age or hsCRP. When the subjects were divided into five groups (0-4) according to the number of metabolic factors (obesity, diabetes, hypertension and dyslipidemia), PEDF levels in patients with four factors were significantly higher than those in patients without factors. Next, we divided the patients into quartiles according to their plasma PEDF levels (〈 9.9 μg/mL, 9.9-12.8, 12.9- -15.7, 〉 15.7). The eGFR in the first group was significantly higher than those in the third and fourth groups. Multivariate logistic analysis indicated that eGFR (p 〈 0.0001) and age (p = 0.030) were significant independent variables that correlated with the quartile classification according to PEDF levels. This study revealed that PEDF may play a role in renal dysfunction in CAD patients.
    Cardiology journal 01/2011; 18(5):515-20. · 1.15 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: This study was performed to evaluate the safety and efficacy of additional antihypertensive therapy with angiotensin II type 1 receptor blocker (ARB; olmesartan or valsartan) after successful stent implantation in patients with coronary artery disease (CAD). Fifty patients with CAD after successful stent implantation were included in this study. They were divided into an ARB group, which initially received olmesartan (n=20, 14+/-8 mg day(-1)) or valsartan (n=20, 60+/-23 mg day(-1)) immediately after stent implantation, and a non-ARB group (n=10) according to their blood pressure (BP). Follow-up coronary angiography, measurement of BP and blood sampling were performed before (at baseline) and 6-8 months after stent implantation (at follow-up). There were no significant differences in the baseline characteristics between the groups, except for BP. Although there were no changes in % diameter restenosis between the groups, the BP level in the ARB group at follow-up showed a significant reduction (125+/-12/69+/-9 mm Hg) and reached the target BP. There were no critical adverse effects in the ARB group throughout the study period. In addition, serum high-sensitive C-reactive protein (hs-CRP) and pentraxin 3 were significantly decreased in the ARB group but not in the non-ARB group. Although olmesartan and valsartan induced similar BP-lowering effects, olmesartan but not valsartan induced a significant decrease in hs-CRP, but did not increase serum uric acid. In conclusion, antihypertensive therapy with add-on low-dose ARB after stent implantation was safe and achieved the target BP. In particular, olmesartan had an anti-inflammatory effect.
    Hypertension Research 06/2009; 32(7):625-30. · 2.79 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Although several clinical studies have evaluated plasma adiponectin levels in response to chronic heart failure, little is known about the relation between cardiac function and metabolic factors including adiponectin in patients with acute myocardial infarction (AMI). We analyzed 50 consecutive patients with AMI who had undergone successful coronary stent implantation. Echocardiography and blood sampling were performed at 1 week and 6 months after AMI. Blood was analyzed with regard to brain natriuretic peptide (BNP) and metabolic factors including plasma levels of adiponectin, lipid profile, and hemoglobin A1c (HbA1c). Plasma adiponectin levels were significantly increased at 6 months (7.3 ± 4.9 μg/ml) compared to those at 1 week (6.1 ± 3.7). BNP (from 156 ± 151 to 96 ± 124 pg/ml) significantly decreased. In addition, BNP at 6 months was positively correlated with plasma adiponectin levels at 1 week (y = 0.019 x -23.1, r = 0.537, P = 0.002), while BNP at 6 months was not associated with maximal creatinine kinase after AMI. A multiple regression analysis was performed to analyze the relationship between BNP at 6 months and metabolic factors (plasma levels of adiponectin, lipid profile, HbA1c, blood pressure, age, sex, and body mass index) at 1 week after AMI. BNP at 6 months was most closely correlated with plasma levels of adiponectin at 1 week (P = 0.045). Among the metabolic factors examined, a higher adiponectin level at 1 week is the predictor of a higher BNP as one marker of cardiac dysfunction at 6 months after AMI.
    Journal of Cardiology 03/2009; 53(1):65-71. · 2.30 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: We describe the case of a 43-year-old primiparous woman who had acute myocardial infarction. She underwent successful primary percutaneous coronary intervention. Elective cesarean section was performed uneventfully at 32 weeks gestation.
    Internal Medicine 02/2009; 48(16):1383-6. · 0.97 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: We describe the case of an 85-year-old woman in whom pericardiocentesis, prolonged bed rest and blood pressure control were performed without surgery to successfully treat an oozing-type myocardial rupture due to myocardial infarction.
    Internal Medicine 02/2008; 47(20):1803-5. · 0.97 Impact Factor